Liposomal drug formulations in cancer therapy: 15 years along the road

• Published in: Drug discovery today Vol. 17; no. 3-4; pp. 160 - 166
• Main Authors: Slingerland, Marije, Guchelaar, Henk-Jan, Gelderblom, Hans
• Format: Journal Article
• Language: English
• Published: Kidlington Elsevier Ltd 01-02-2012; Elsevier
• Subjects: Antineoplastic Agents - administration & dosage; Antineoplastic Agents - adverse effects; Antineoplastic Agents - therapeutic use; Biological and medical sciences; Clinical Trials as Topic; Doxorubicin - administration & dosage; Doxorubicin - adverse effects; Doxorubicin - therapeutic use; Drug Approval; Drug Carriers - chemistry; Drug Design; General pharmacology; Humans; Liposomes; Medical sciences; Neoplasms - drug therapy; Neoplasms - pathology; Pharmaceutical technology. Pharmaceutical industry; Pharmacology. Drug treatments; Drug; Pharmaceutical technology; Treatment; Formulation; Liposome; Malignant tumor; Cancer
• ISSN: 1359-6446; 1878-5832
• DOI: 10.1016/j.drudis.2011.09.015

Liposomes as pharmaceutical drug carriers were developed to increase antitumour efficacy and decrease drug toxicity. Doxorubicin HCl liposomal injection was the first liposomal encapsulated anticancer drug to receive clinical approval. To date, virtually all traditional anticancer drugs have been encapsulated in liposomes.
The majority of clinical studies only support the concept of a decreased toxicity and better tolerability of the liposomal anticancer drug. Although liposomal anticancer drugs have grown to maturity in several indications and are now in widespread further development programmes using their theoretical advantages to fulfil the high expectations, further studies are warranted – including the development of novel liposomal formulations.